Trial Profile
Phase-1 Study of Escalated-dose Pelvic Radiation Therapy Using Intensity-Modulated Radiotherapy (IMRT) With Simultaneous Integrated Boost (SIB), in Combination With Xeloda, for Initially Metastatic, Low and Middle Rectal Cancer
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 16 May 2019
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Fluorouracil; Oxaliplatin
- Indications Rectal cancer
- Focus Adverse reactions
- Acronyms DESIR
- 13 May 2019 Status changed from recruiting to discontinued for lack of inclusion
- 23 Aug 2018 New trial record